

## ASX Announcement

20 July 2023

---

### Intention to launch Share Purchase Plan

#### Key Highlights:

- Antisense proposes to launch a Share Purchase Plan at an offer price of \$0.05 per share, providing eligible shareholders the opportunity to participate in the capital raising on the same terms as institutional investors under the recently announced institutional placement
- The funds raised will enable Antisense to advance its ongoing international Phase IIb study of ATL1102 in Duchenne muscular dystrophy, and for working capital purposes

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (**Antisense** or **Company**) is pleased to announce that it proposes to undertake a share purchase plan (**SPP**) for eligible existing shareholders, to provide an opportunity for them to participate in the capital raising on the same terms as investors under the institutional placement (**Placement**) of new shares in the Company that raised \$8.35 million, as announced on 18 July 2023.

The Company will offer eligible shareholders of the Company with a registered address in Australia or New Zealand as at 7:00pm (AEST) on 19 July 2023, the opportunity to participate in the SPP.

The SPP will be offered at \$0.05 per share (being a 18.0% discount to the last traded price), which is the same price as the Placement.

The SPP is targeting to raise approximately \$1.5 million.

The Antisense Board of Directors reserves absolute discretion regarding the final amount raised under the SPP including to scale back offers received under the SPP or increase or decrease the amount to be raised under the SPP. Individual applications for SPP shares will be capped at the statutory maximum of \$30,000 per eligible shareholder across all their holdings (free of any brokerage, commission and transaction costs). The SPP will not be underwritten.

The SPP shares will be issued pursuant to Exception 5 in ASX Listing Rule 7.2 and will not count towards Antisense's placement capacity. The capital raised under the SPP will be used for the same purpose as funds raised under the Placement.

Eligible shareholders wishing to participate in the SPP should carefully read the SPP Offer Booklet which is scheduled to be dispatched to eligible shareholders in Australia and New Zealand and released on ASX on 28 July 2023, and which will contain full details of the SPP.

Key dates for the SPP are set out below.

## **Key Dates Share Purchase Plan**

<b>Event</b>	<b>Date* (Australian Eastern Standard Time)</b>
Record Date for the SPP	Wednesday, 19 July 2023
Settlement of New Shares under the Placement	Friday, 21 July 2023
Allotment and commencement of trading of New Shares under the Placement	Monday, 24 July 2023
Dispatch SPP booklet to Shareholders	Friday, 28 July 2023
SPP opens	Friday, 28 July 2023
SPP closes	Wednesday, 16 August 2023
Announcement of results of the SPP	Monday, 21 August 2023
Allotment of New Shares under the SPP	Tuesday, 22 August 2023
Quotation on ASX of New Shares under the SPP	Wednesday, 23 August 2023

The timetable is indicative only and subject to change. The Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).

### **For more information please contact:**

#### **Antisense Therapeutics**

Charmaine Gittleson  
 Executive Chair  
 +61 (0)3 9827 8999  
[www.antisense.com.au](http://www.antisense.com.au)

#### **Investment Enquiries**

Gennadi Koutchin  
 XEC Partners  
[gkoutchin@xecpartners.com.au](mailto:gkoutchin@xecpartners.com.au)  
 1300 932 037

#### **US/European IR & Media**

Laine Yonker/Joe Green  
 Edison Investor Relations  
[lyonker@edisongroup.com](mailto:lyonker@edisongroup.com)  
 +1 646-653-7035

*This announcement has been authorised for release by the Board.*

**About Antisense Therapeutics Limited** [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial.